Federico Longo-Muñoz

The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer

Eric Van Cutsem, R. Mayer, Stéphanie Laurent et al. · European Journal of Cancer · 2017 · 99 citations · Full text

Medicine, Oncology, Pharmacology +13

First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD)

Alfredo Carrato, Albert Abad, Bartomeu Massutí et al. · European Journal of Cancer · 2017 · 88 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Does Rapid Drug Desensitization to Chemotherapy Affect Survival Outcomes?

MP Berges-Gimeno, LV Carpio-Escalona, Federico Longo-Muñoz et al. · Journal of Investigational Allergology and Clinical Immunology · 2019 · 35 citations · Full text

Medicine, Oncology, Pharmacology +13

Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECOURSE trial

Federico Longo-Muñoz, Guillem Argilés, Josep Tabernero et al. · Clinical & Translational Oncology · 2016 · 32 citations · Full text

Medicine, Oncology, Pharmacology +14

Association of the Lung Immune Prognostic Index with Immunotherapy Outcomes in Mismatch Repair Deficient Tumors

Édouard Auclin, Perrine Vuagnat, Cristina Smolenschi et al. · Cancers · 2021 · 14 citations · Full text

Medicine, Immunology, Oncology +17